# OnCo record orient-4 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/orient-4/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "orient-4", "NCT03228836" ;
  schema:name "ORIENT-4"@en ;
  schema:alternateName "Sintilimab in relapsed NK/T-cell lymphoma"@en, "IBI308 in extranodal NK/T-cell lymphoma"@en ;
  schema:description "A PD-1 antibody given alone shrank the lymphoma in three out of four people whose NK/T-cell lymphoma had come back after asparaginase chemotherapy."@en ;
  schema:url <https://onco.cc/trials/orient-4/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03228836>, <https://doi.org/10.1038/s41392-021-00768-0> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence-entities" ;
  onco:phase "2" ;
  schema:startDate "2017-08-23" ;
  onco:cancers <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/sintilimab/> ;
  onco:companies <https://onco.cc/companies/innovent/> ;
  onco:terms <https://onco.cc/terms/orr/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-orient-4-sintilimab-nk-t-cell-lymphoma-2021/> .